Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc. is a biopharmaceutical company primarily engaged in developing and commercializing innovative treatments for medical conditions related to addiction and other central nervous system (CNS) disorders. The company's main focus is on developing proprietary therapeutics that cater to unmet medical needs. A key product in their lineup is Probuphine, a unique, long-acting implant for the continuous release of buprenorphine, which is used to treat opioid addiction. Titan Pharmaceuticals Inc. actively collaborates with healthcare professionals and other companies to bring these solutions to market effectively. Headquartered in South San Francisco, California, Titan plays a significant role in the biotechnology sector by driving advancements in addiction treatment. The company's initiatives are essential in addressing the growing opioid crisis, thus positioning it as an influential player in the life sciences and therapeutics industry. Titan Pharmaceuticals Inc. seeks to leverage its expertise in drug delivery systems and CNS-focused treatments to enhance patient care and provide sustainable treatment options.